Molecular biology of von Willebrand disease

被引:0
作者
Melo-Nava, Brenda [1 ]
Penaloza, Rosenda [1 ]
机构
[1] IMSS, Ctr Med Nacl Siglo 21, Hosp Pediat, Unidad Invest Med Genet Humana, Mexico City 06700, DF, Mexico
来源
REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2007年 / 59卷 / 05期
关键词
von Willebrand factor; von Willebrand disease; bleeding; coagulation;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Von Willebrand Factor (VWF) is a large multimeric glycoprotein expressed in the megakaryocytes and endothelial cells of all vertebrates. It participates fundamentally in the primary and secondary hemostasis because it induces the adhesion of platelets to vascular subendothelium and promotes aggregation of platelets when blood vessels and capillaries are damaged. In addition, VWF links to factor VIII which avoids its proteolysis. The deficiency or the inadequate synthesis of the VWF causes von Willebrand disease (VWD), which is the most common hereditary bleeding disorder in humans principally from mucous and cutaneous sites. VWD is difficult to detect with accuracy due to interrelation among VWF with different components of hemostasis, although it is performed by different tests of haemostatic system, and the basic mechanisms in VWD are herein emphasized. The diagnosis of VWD is difficult due to the heterogeneous manifestation of the disease, which also complicates its classification. This article focuses on the molecular aspects of the disease and discusses their possible clinical implications.
引用
收藏
页码:401 / 408
页数:8
相关论文
共 50 条
  • [31] Treatment of von Willebrand Disease
    Curnow, Jennifer
    Pasalic, Leonardo
    Favaloro, Emmanuel J.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2016, 42 (02) : 133 - 146
  • [32] Treatment of von Willebrand disease
    Mannucci, PM
    THROMBOSIS AND HAEMOSTASIS, 2001, 86 (01) : 149 - 153
  • [33] von Willebrand disease in China
    Wang, YC
    Li, ZY
    Gu, JM
    Ruan, CG
    CHINESE MEDICAL JOURNAL, 2000, 113 (08) : 677 - 680
  • [34] Von Willebrand disease in dogs
    Wessely-Szponder, J
    MEDYCYNA WETERYNARYJNA, 1999, 55 (05) : 288 - 291
  • [35] von Willebrand disease: still an intriguing disorder in the era of molecular medicine
    Rodeghiero, F
    HAEMOPHILIA, 2002, 8 (03) : 292 - 300
  • [36] Molecular characterization of Iranian patients with type 3 von Willebrand disease
    Shahbazi, S.
    Mahdian, R.
    Ala, F. A.
    Lavergne, J. -M.
    Denis, C. V.
    Christophe, O. D.
    HAEMOPHILIA, 2009, 15 (05) : 1058 - 1064
  • [37] Treatment of von Willebrand disease
    Mannucci, PM
    HAEMOPHILIA, 1998, 4 (04) : 661 - 664
  • [38] VON WILLEBRAND DISEASE: CLINICAL, COAGULOGICAL, MOLECULAR AND GENETIC DATA COMPARISON
    Chernetskaya, D. M.
    Likhacheva, E. A.
    Pshenichnikova, O. S.
    Surin, V. L.
    Zozulya, N., I
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2019, 64 (03): : 246 - 255
  • [39] Assessment of von Willebrand Factor Propeptide Improves the Diagnosis of von Willebrand Disease
    Casonato, Alessandra
    Daidone, Viviana
    Padrini, Roberto
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2011, 37 (05) : 456 - 463
  • [40] Prophylaxis in von Willebrand disease with von Willebrand factor concentrate and nonfactor therapies
    Kwawegen, Calvin B. van
    Leebeek, Frank W. G.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (08)